Bernard Daugeras
Co-founder @ Auriga Partners
Bernard Daugeras is a Series A investor at Auriga Partners focused on Medical and Nutrition. Co-founder Chairman of the Board of Auriga Partners, Bernard is an expert in Life Sciences and was behind successful investments such as BioAlliance Pharma , NicOx. He is a member of the French Academy of Technologies. Bernard began his career doing research into particle physics at the University of Orsay, the University of California atBerkeley, and CNRS, the French national scientific research center. He subsequently held senior posts at the French Ministry of Industry and Research, where he was in charge of promoting technology transfer from research institutions and of optimizing relations between Research and Industry. After 4 years in the Crédit Lyonnais setting up the bank's Venture Capital arm, he joined Finovelec in 1990. Bernard is a graduate of the Ecole Polytechnique and has a PhD from the University of Orsay.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Bernard Daugeras invests in
Stages Bernard Daugeras invests in
Countries Bernard Daugeras invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (20%)
- Nutrition 1 (20%)
- Health Care 1 (20%)
- Therapeutics 1 (20%)
- Biotechnology 1 (20%)
Stage
- Series A 2 (40%)
- Series B 1 (20%)
- Series C 1 (20%)
- Funding Round 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identifyorthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs. | $9M / Series C / Oct 01, 2006 | ||
| Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identifyorthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs. | $17.6M / Series B / May 01, 2004 | ||
| Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identifyorthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs. | $3.3M / Series A / Feb 01, 2002 | ||
| Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identifyorthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs. | $2.2M | ||
| GliSODin Skin Nutrients is a professional medical line of nutricosmetics focused on optimal internal support. It provides the skin with essential nutrients and functions to protect it from the effects of oxidative stress. GliSODin Skin Nutrients was founded in 2008 and is based in Paris, France. | $3.3M / Series A |
Co-Investors
About Auriga Partners
Since 1998, AURIGA PARTNERS, an independent Venture Capital firm, has been managing several early stage funds specializing in Information Technology and Life Sciences.
Auriga Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Sébastien Descarpentries
Partner
|
|||
Anne Sossou Hounto
Legal assistant
|
|||
Arnaud-Guilhem Le Ribault
Partner
|
|||
|
Bernard Daugeras
Co-founder
|
|||
Françoise Lugand
Office manager
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Bernard Daugeras invest in?
Bernard Daugeras invests primarily in Medical, Nutrition and Health Care startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Bernard Daugeras?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Bernard Daugeras last invest?
The most recent investment recorded for Bernard Daugeras closed in Oct 2006. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
